Short-term (4-8 weeks) treatment of severe erosive esophagitis (grade 2 or above), diagnosed by endoscopy and short-term treatment of symptomatic gastroesophageal reflux disease (GERD) poorly responsive to customary medical treatment; pathological hypersecretory conditions; peptic ulcer disease; gastric ulcer therapy; approved for combination use in the eradication of H. pylori in patients with active duodenal ulcer.

In long-term (2-year) studies in rats, omeprazole produced a dose-related increase in gastric carcinoid tumors. While available endoscopic evaluations and histologic examinations of biopsy specimens from human stomachs have not detected a risk from short-term exposure to omeprazole, further human data on the effect of sustained hypochlorhydria and hypergastrinemia are

Known hypersensitivity to omeprazole

1% to 10%: Cardiovascular: Angina, tachycardia, bradycardia, edema Central nervous system: Headache (7%), dizziness; Dermatologic: Rash, urticaria, pruritus, dry skin; Gastrointestinal: Diarrhea, nausea, abdominal pain, vomiting, constipation, anorexia, irritable colon, fecal discoloration, esophageal candidiasis, xerostomia, abnormal taste;

Genitourinary: Testicular pain, urinary tract infection, polyuria; Neuromuscular & skeletal: Back pain, muscle cramps, myalgia, arthralgia, leg pain, weakness occurred in more frequently than 1% of patients; Renal: Pyuria, proteinuria, hematuria, glycosuria; Respiratory: Cough.
< 1 % : Chest pain, fever, fatigue, malaise, apathy, somnolence, nervousness, anxiety, pain, abdominal swelling

Decreased effect: ketoconazole; itraconazole.
Increased toxicity: Diazepam may increase half-life; increased digoxin, increased phenytoin, increased warfarin.

Symptoms of overdose include hypothermia, sedation, convulsions, decreased respiratory rate.
Treatment is supportive; not dialyzable.

Take before eating; do not chew, crush, or open capsule